U.S. Markets close in 1 hr 48 mins
  • S&P 500

    4,144.80
    -43.63 (-1.04%)
     
  • Dow 30

    34,212.33
    -530.49 (-1.53%)
     
  • Nasdaq

    13,359.79
    -42.07 (-0.31%)
     
  • Russell 2000

    2,207.19
    -5.51 (-0.25%)
     
  • Crude Oil

    65.26
    +0.34 (+0.52%)
     
  • Gold

    1,835.90
    -1.70 (-0.09%)
     
  • Silver

    27.68
    +0.19 (+0.70%)
     
  • EUR/USD

    1.2155
    +0.0021 (+0.1702%)
     
  • 10-Yr Bond

    1.6220
    +0.0200 (+1.25%)
     
  • Vix

    21.65
    +1.99 (+10.12%)
     
  • GBP/USD

    1.4149
    +0.0028 (+0.1953%)
     
  • USD/JPY

    108.6470
    -0.1940 (-0.1782%)
     
  • BTC-USD

    56,405.61
    -697.76 (-1.22%)
     
  • CMC Crypto 200

    1,506.75
    +1,264.07 (+520.88%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BIIB, YY and OTGLY

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / January 12, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Biogen Inc. (NASDAQ:BIIB)
Class Period: October 22, 2019 - November 6, 2019
Lead Plaintiff Deadline: January 12, 2021

Throughout the class period, Biogen Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in BIIB: http://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form?id=12099&from=1

Joyy Inc. (NASDAQ:YY)
Class Period: April 28, 2016 - November 18, 2020
Lead Plaintiff Deadline: January 19, 2021

The YY lawsuit alleges that Joyy Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) The majority of users at any given time were bots; (2) the Company utilized these bots to effect a roundtripping scheme that Manufactured the false appearance of revenues; (3) the Company overstated its cash reserves; (4) the Company's acquisition of Bigo was largely contrived to benefit corporate insiders; and (5) as a result, Defendants' public statements were materially false and/or Misleading at all relevant times.

Learn about your recoverable losses in YY: http://www.kleinstocklaw.com/pslra-1/joyy-inc-loss-submission-form?id=12099&from=1

CD Projekt S.A. (OTCMKT:OTGLY)
Class Period: January 16, 2020 - December 17, 2020
Lead Plaintiff Deadline: February 22, 2021

According to the complaint, CD Projekt S.A. allegedly made materially false and/or misleading statements and/or failed to disclose that: Throughout the class period, defendants were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company's business, operations and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Cyberpunk 2077 was virtually unplayable on the current-generation Xbox or Playstation systems due to an enormous number of bugs; (2) as a result, Sony would remove Cyberpunk 2077 from the Playstation store, and Sony, Microsoft and the Company would be forced to offer full refunds for the game; (3) consequently, the Company would suffer reputational and pecuniary harm; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in OTGLY: http://www.kleinstocklaw.com/pslra-1/cd-projekt-s-a-loss-submission-form?id=12099&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/623966/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-BIIB-YY-and-OTGLY